Condition
Pernicious Anemia
Total Trials
3
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+14% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
1Total
P 4 (1)
Trial Status
Completed3
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT04239521Completed
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
NCT03372447Phase 4Completed
Megadose of Hydroxocobalamin for the Treatment of Pernicious Anemia
NCT03941184Completed
Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity
Showing all 3 trials